Get to Know the Journal CHEST Editor in Chief

Peter J. Mazzone, MD, MPH, FCCP, is a pulmonologist at the Cleveland Clinic. He currently directs the Lung Cancer Program for the Respiratory Institute of the Cleveland Clinic and the Lung Cancer Screening Program and Nodule Management Program for the Cleveland Clinic.

He is currently the Editor in Chief of the journal CHEST^®, having seen the journal through many changes since taking the helm in 2019. He also has served on the Steering Committee, then as Vice-Chair and Chair of CHEST’s Thoracic Oncology Network. He served as Vice-Chair and then Chair of the Program Committee for the CHEST Annual Meeting. He has been a member of the Lung Cancer Guidelines Executive Committee, authored guideline chapters, and led successive CHEST lung cancer screening guidelines. He led a position statement about high-quality lung cancer screening that resulted in CHEST being represented at an advocacy meeting with the Centers for Medicare & Medicaid Services. He is an FCCP, a Master Educator of the college, and has given multiple lectures at the annual meetings and programs at headquarters.

Dr. Mazzone has also served as Chairman of the Planning Committee of the Thoracic Oncology Assembly of the American Thoracic Society. He is a member of the Steering Committee for the American Cancer Society Lung Cancer Roundtable and a member of the American Lung Association Lung Cancer Expert Medical Advisory Panel. Projects that he has led for these societies have resulted in policy statements about the components of a high-quality lung cancer screening program, the clinical utility of molecular biomarkers for early lung cancer detection, and quality indicators for the diagnosis and staging of lung cancer.

In addition, Dr. Mazzone has been a reviewer for the National Institutes of Health Cancer Biomarkers Study Section and for the Agency for Healthcare Research and Quality. He has performed discovery and clinical validation level research related to the development of breath-, blood-, and urine-based biomarkers for the early detection of lung cancer and has hosted collaborative meetings related to the progress of early lung cancer detection technologies.